AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

Bruker Corporation (Nasdaq: BRKR) is showcasing some of its latest innovations at Analytica 2024.

Collaboration aims to grow clinical evidence supporting the use of bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.

HORIBA Instruments Inc., is proud to announce the launch of their dedicated product solutions to address the impacts of microplastics on the environment and life forms.

Sebastian Arevalo's appointment strategically positions RedShiftBio to capitalize on growing opportunities in the biophysical characterization and bioprocess analytics markets, leveraging a proven track record in driving sales growth.

Highly sensitive and multiplexed assay for the detection, discrimination, and quantification of key mutations in ESR1 gene for breast cancer, developed for bio-Rad’s QX600™ droplet digital™ PCR system.